Reuters
Published Feb 08, 2023 09:43AM ET
Updated Feb 08, 2023 11:39AM ET
By Foo Yun Chee
BRUSSELS (Reuters) - U.S. life science company Illumina (NASDAQ:ILMN) on Wednesday took its case to senior EU and national antitrust officials at a closed hearing to argue against an EU antitrust order that it divests cancer detection test maker Grail Inc.
Illumina had completed a takeover of Grail in August 2021, without securing European Union regulatory approval. The European Commission ordered Illumina in December to unwind the deal, three months after it had blocked the merger on concerns the deal would stifle innovation.
Illumina has said the EU competition enforcer should not have examined the case as the companies do not meet a revenue threshold stipulated by EU merger rules.
"We disagree that the Commission has jurisdiction to review the Grail transaction and believe that divestment is not proportional to the speculative harm the Commission has alleged," Illumina said in a statement ahead of the hearing.
"Any divestment order should be stayed until our appeal of the Commission's prohibition decision has been resolved," it said.
Companies usually take the opportunity at such hearings to persuade senior EU and national competition officials of the pro-competitive advantages of their deals.
Illumina has three appeals pending in Europe's top courts, against the EU enforcer's ruling that it jumped the gun by closing the deal without securing approval, the EU's subsequent veto, and the EU decision to examine the case in the first place.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.